NCT03751111View on ClinicalTrials.gov

Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

March 1, 2019

Study Completion Date

March 30, 2019

Conditions
Chronic Pruritus
Interventions
DRUG

Naloxone

Naloxone at an sublingual dose of 0.4 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.

DRUG

Placebo

Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.

Trial Locations (1)

410008

Xiangya Hospital, Changsha

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER

NCT03751111 - Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone | Biotech Hunter | Biotech Hunter